| Nhc Healthcare - Bluffton | |
| 3039 Okatie Highway, Okatie, South Carolina 29909 | |
| (843) 705-8220 | |
| Name | Nhc Healthcare - Bluffton |
|---|---|
| Location | 3039 Okatie Highway, Okatie, South Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 81.58% |
| Medicare ID (CCN) | 425397 |
| Legal Business Name | Nhc Healthcare-bluffton Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1336544998 |
| Organization Name | JESSICA L KURPIS |
| Address | 3039 Okatie Hwy, Bluffton, SC 29909 |
| Phone Number | 843-705-8224 |
News Archive
Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.
For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.
Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.
Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.
A new study suggests that middle-age and elderly men are less likely to develop worsening frailty if they have high levels of certain anabolic hormones, which are muscle- and bone-building hormones.
› Verified 5 days ago
| NPI Number | 1568791051 |
| Organization Name | NHC HEALTHCARE-BLUFFTON LLC |
| Doing Business As | NHC HEALTHCARE, BLUFFTON |
| Address | 3039 Okatie Hwy, Bluffton, SC 29909 |
| Phone Number | 843-705-8220 |
News Archive
Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.
For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.
Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.
Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.
A new study suggests that middle-age and elderly men are less likely to develop worsening frailty if they have high levels of certain anabolic hormones, which are muscle- and bone-building hormones.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.
For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.
Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.
Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.
A new study suggests that middle-age and elderly men are less likely to develop worsening frailty if they have high levels of certain anabolic hormones, which are muscle- and bone-building hormones.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.35 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.55 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 68.42 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.05 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 10.11 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 30.58 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.7 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19.31 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.54 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.48 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 29.08 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 33.33 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.79 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.21 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.69 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.5 | 82.93 |
News Archive
Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.
For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.
Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.
Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.
A new study suggests that middle-age and elderly men are less likely to develop worsening frailty if they have high levels of certain anabolic hormones, which are muscle- and bone-building hormones.
› Verified 5 days ago
Nhc Healthcare - Bluffton Location: 3039 Okatie Highway, Okatie, South Carolina 29909 Phone: (843) 705-8220 |